PATENT CLAIM ANALYSIS

Application Number: 16041237
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-04
Patent Classification: ["514", "005100"]

Abstract:
Provided are immediate or prolonged administration of certain potassium ATP (K ATP ) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K ATP  channels. Also provided are pharmaceutical formulations, methods of administration and dosing of K ATP  channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering K ATP  channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.

Claim (Index 32):
The method of  claim 29 , wherein the pharmaceutical formulation is administered once per day.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 95.0
- Lexical Diversity: 1.87324
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15671792', '14940018', '14458032', '15195826', '12391990']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7584337648763652
- 35 USC 102 Novelty (BERT): 0.5419942143034846
- Combined Prediction Score: 0.7367898098190772
- Mean Citation Score: 340.741102
- Max Citation Score: 368.0851
- Similarity Product: 242.2678301781416

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test